Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06528431
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-19
Brief Title:
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage the MONITORA Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage the MONITORA Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MONITORA
Brief Summary:
Rheumatoid arthritis RA is the most common inflammatory joint disorder Since twenty year and the use of synthetic disease-modifying anti-rheumatic drugs csDMARDs and biological bDMARD remission can be reached When remission is obtained the physician has no recommendations for managing a step-down and future guidelines will be useful to assist the clinician Recent data suggest that tapering is feasible but with high risk of flares Flares are less frequent when bDMARD blood concentration is high But the optimal adalimumab concentration to keep before a step of tapering no targeting personal is unknown
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None